Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of Vascular Endothelial Growth Factor (VEGF, green) in Hela cells. The cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS, and blocked with 3% Blocker BSA (Product # 37525) for 30 minutes at room temperature. Cells were stained with (left panel) or without (right panel) a VEGF polyclonal antibody (Product # MA5-12184) at a dilution of 1:40 for at least 1 hour at room temperature, and then incubated with a Dylight 488 goat anti-Mouse IgG secondary antibody at a dilution of 1:1000 for 45 minutes at room temperature. F-actin (both panels, red) was stained by Dylight 554 Phalloidin (Product # 21834) and nuclei (both panels, blue) were stained with DAPI (Product # 46190). Images were taken at 60X magnification.
|Tested species reactivity||Human|
|Published species reactivity||Rabbit, Rat, Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Recombinant VEGF189 protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100-1:200|
|Western Blot (WB)||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-12184 targets Vascular Endothelial Growth Factor in IF, IHC (P) and WB applications and shows reactivity with Human samples.
VEGF which is a homodimeric, disulfide-linked glycoprotein involved in angiogenesis which promotes tumor progression and metastasis. It exhibits potent mitogenic and permeability inducing properties specific for the vascular endothelium. Of the four isoforms of VEGF, the smaller two, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two (VEGF189 and VEGF206) remain cell associated.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
The Eyes Absent Proteins in Developmental and Pathological Angiogenesis.
MA5-12184 was used in immunocytochemistry to study proteins absent in the eyes during pathological and developmental angiogenesis
|Wang Y,Tadjuidje E,Pandey RN,Stefater JA,Smith LE,Lang RA,Hegde RS||The American journal of pathology (186:568)||2016|
Temporal and pharmacological characterization of angiostatin release and generation by human platelets: implications for endothelial cell migration.
MA5-12184 was used in immunocytochemistry to study the production and release of angiostatin by human platelets
|Radziwon-Balicka A,Moncada de la Rosa C,Zielnik B,Doroszko A,Jurasz P||PloS one (8:null)||2013|
The role of thrombin receptors PAR1 and PAR4 for PAI-1 storage, synthesis and secretion by human platelets.
MA5-12184 was used in immunocytochemistry to study the production and secretion of PAI-1 by human platelets and the roles played by the the PAR1 and PAR4 thrombin receptors
|Nylander M,Osman A,Ramström S,Aklint E,Larsson A,Lindahl TL||Thrombosis research (129:e51)||2012|
Coronary thrombi neovascularization in patients with ST-elevation myocardial infarction - clinical and angiographic implications.
MA5-12184 was used in immunohistochemistry to evaluate thrombi from patients with ST-elevation myocardial infarction
|Kosti¿ J,Orli¿ D,Borovi¿ ML,Beleslin B,Mila¿inovi¿ D,Dobri¿ M,Te¿i¿ M,Ostoji¿ M||Thrombosis research (134:1038)||2014|
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study.
MA5-12184 was used in immunohistochemistry to study the immunohistochemical expression of VEGF and VEGFR isoforms in patients with thymic epithelial tumors
|Lattanzio R,La Sorda R,Facciolo F,Sioletic S,Lauriola L,Martucci R,Gallo E,Palmieri G,Evoli A,Alessandrini G,Ruco L,Rendina EA,Truini M,Chiarle R,Barreca A,Pich A,Ascani S,Remotti D,Tunesi G,Granone P,Ratto GB,Puma F,Pescarmona E,Piantelli M,Marino M,Carlini S,Cerasoli V,Corzani F,Melis E,Filippetti M,Canalini P,Palestro G,Lalle M,Ruffini E,Ceribelli A,Rinaldi M||Lung cancer (Amsterdam, Netherlands) (85:191)||2014|
Biological and demographic profile of meningiomas in a cohort of Egyptian patients: impact on tumor recurrence.
MA5-12184 was used in immunohistochemistry to study the relationship between meningioma biological and demographic profiles and disease recurrence in Egyptian patients
|Abdelzaher E,El Deeb NM,Gowil AG,Yehya A||TheScientificWorldJournal (2013:null)||2014|
Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma.
MA5-12184 was used in immunohistochemistry to study the expression of PTHrP, EPO and VEGF in clear cell renal cell carcinoma and their relationships with tumor grade
|Feng CC,Ding GX,Song NH,Li X,Wu Z,Jiang HW,Ding Q||Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (34:3471)||2013|
The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients.
MA5-12184 was used in immunohistochemistry to study the effect of breast cancer intrinsic subtype on cliniopathological and biomarker profiles in Japanese patients
|Tamaki M,Kamio T,Kameoka S,Kojimahara N,Nishikawa T||World journal of surgical oncology (11:null)||2013|
Paraneoplastic symptoms: cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma.
MA5-12184 was used in immunohistochemistry to study the relationship between expression of VEGF and the development of paraneoplastic symptoms in patients with renal clear cell carcinoma
|Ding GX,Feng CC,Song NH,Fang ZJ,Xia GW,Jiang HW,Hua LX,Ding Q||Urologic oncology (31:1820)||2013|
Mesenchymal-to-endothelial transition in Kaposi sarcoma: a histogenetic hypothesis based on a case series and literature review.
MA5-12184 was used in immunohistochemistry to develop a hypothesis of Kaposi sarcoma histogenesis based on a case and literature review
|Gurzu S,Ciortea D,Munteanu T,Kezdi-Zaharia I,Jung I||PloS one (8:null)||2013|
Resveratrol treatment delays growth plate fusion and improves bone growth in female rabbits.
MA5-12184 was used in immunohistochemistry to study the potential mechanisms involved in the delayed growth plate fusion and increased longitudonal bome growth observed in female rabbits treated with resveratrol
|Karimian E,Tamm C,Chagin AS,Samuelsson K,Kjartansdóttir KR,Ohlsson C,Sävendahl L||PloS one (8:null)||2013|
The effect of lipoic acid on wound healing in a full thickness uterine injury model in rats.
MA5-12184 was used in immunohistochemistry to use a rat full thickness uterine injury model to study the beneficial effects of lipoic acid on wound healing
|Micili SC,Goker A,Sayin O,Akokay P,Ergur BU||Journal of molecular histology (44:339)||2013|
The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model.
MA5-12184 was used in immunohistochemistry to compare the therapeutic effects of bevacizumab, sorafenib and nicotinic acid in a rat model of endometriosis
|Ozer H,Boztosun A,Açmaz G,Atilgan R,Akkar OB,Kosar MI||Reproductive sciences (Thousand Oaks, Calif.) (20:26)||2013|
Pulmonary artery sarcoma with angiosarcoma phenotype mimicking pleomorphic malignant fibrous histiocytoma: a case report.
MA5-12184 was used in immunohistochemistry to report on a case of pulmonary artery sarcoma
|Bohn OL,de León EA,Lezama O,Rios-Luna NP,Sánchez-Sosa S,Llombart-Bosch A||Diagnostic pathology (7:null)||2012|
Prediction of the shrinking rate of uterine leiomyoma nodules using needle biopsy specimens.
MA5-12184 was used in immunohistochemistry to study the relationship between the shrinking of uterine leiomyoma nodules and the expression of ER, PR and VEGF following menopause or pharmacological treatment
|Kasai M,Ichimura T,Kawamura N,Sumikura T,Matsuda M,Asano C,Sumi T,Ishiko O||Fertility and sterility (98:440)||2012|
Lipoxin A4 inhibits the development of endometriosis in mice: the role of anti-inflammation and anti-angiogenesis.
MA5-12184 was used in immunohistochemistry to study the anti-inflammatory and anti-angiogenic mechanisms by which lipoxin A4 inhibits endometriosis in a murine model
|Xu Z,Zhao F,Lin F,Chen J,Huang Y||American journal of reproductive immunology (New York, N.Y. : 1989) (67:491)||2012|
Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers.
MA5-12184 was used in immunohistochemistry to study the mechanisms underlying the inhibitory effects of boswellic acid on human colorectal cancer growth and metasatsis in an orthotopic murine model
|Yadav VR,Prasad S,Sung B,Gelovani JG,Guha S,Krishnan S,Aggarwal BB||International journal of cancer (130:2176)||2012|
Immunohistochemical study of the angiogenetic network of VEGF, HIF1¿, VEGFR-2 and endothelial nitric oxide synthase (eNOS) in human breast cancer.
MA5-12184 was used in immunohistochemistry to study the expression of VEGF, VEGFR-2, HIF1-alpha and eNOS in invasive ductal carcinoma
|Kafousi M,Vrekoussis T,Tsentelierou E,Pavlakis K,Navrozoglou I,Dousias V,Sanidas E,Tsiftsis D,Georgoulias V,Stathopoulos EN||Pathology oncology research : POR (18:33)||2012|
Serum and pulmonary vascular endothelial growth factor/receptors and haemodynamic measurements in cyanotic congenital heart disease with decreased pulmonary blood flow.
MA5-12184 was used in immunohistochemistry to study levels of VEGF and VEGFR in the serum and lungs of patients with cyanotic congenital heart disease
|Tolunay I,Tunaoglu S,Akyürek N,Halid V,Olgunturk R,Kula S||Cardiology in the young (21:608)||2011|
Angiogenesis in the progression of breast ductal proliferations.
MA5-12184 was used in immunohistochemistry to study the role of angiogenesis in the progression of breast ductal carcinomas
|Carpenter PM,Chen WP,Mendez A,McLaren CE,Su MY||International journal of surgical pathology (19:335)||2011|
Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma.
MA5-12184 was used in immunohistochemistry to study the role of VEGF, VEGF receptors, EGF receptor and Ki-67 in leiomyosarcoma
|Sanci M,Dikis C,Inan S,Turkoz E,Dicle N,Ispahi C||Acta histochemica (113:317)||2011|
VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma.
MA5-12184 was used in immunohistochemistry to investigate the roles of VEGFR1 and VEGF during lymph node metastasis and differentiated thyroid carcinoma
|Karaca Z,Tanriverdi F,Unluhizarci K,Ozturk F,Gokahmetoglu S,Elbuken G,Cakir I,Bayram F,Kelestimur F||European journal of endocrinology (164:277)||2011|
Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.
MA5-12184 was used in immunohistochemistry to compare expression of Maspin, VEGF, and p53 between carcinomas
|Bircan A,Bircan S,Kapucuoglu N,Songur N,Ozturk O,Akkaya A||Pathology oncology research : POR (16:553)||2010|
Vascular endothelial growth factor: a possible mediator of endothelial activation in acute respiratory distress syndrome.
MA5-12184 was used in immunohistochemistry to study the potential role of VEGF in mediating endothelial activation in acute respiratory distress syndrome
|Azamfirei L,Gurzu S,Solomon R,Copotoiu R,Copotoiu S,Jung I,Tilinca M,Branzaniuc K,Corneci D,Szederjesi J,Kovacs J||Minerva anestesiologica (76:609)||2010|
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
MA5-12184 was used in immunohistochemistry to compare the effectiveness between cabergoline and meloxicam in the prevention of ovarian hyperstimulation syndrome
|Saylan A,Arioz DT,Koken T,Dilek H,Saylan F,Yilmazer M||Acta obstetricia et gynecologica Scandinavica (89:692)||2010|
Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy.
MA5-12184 was used in immunohistochemistry to identify reliable predictive biomarkers for patients with metastatic renal cell carcinomas
|Kim HS,Kim WS,Park SH,Jung CW,Choi HY,Lee HM,Jeon SS,Ha H,Hwang IG,Lee S,Lim HY||Urologic oncology (28:157)||2010|
Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas.
MA5-12184 was used in immunohistochemistry to study the relationship between HIF-1alpha expression and various prognostic parameters in bladder urothelial carcinomas
|Deniz H,Karakök M,Yagci F,Güldür ME||International urology and nephrology (42:103)||2010|
Anti-human vascular endothelial growth factor (VEGF) antibody selection for immunohistochemical staining of proliferating blood vessels.
MA5-12184 was used in immunohistochemistry to evaluate suitable vascular endothelial growth factor antibodies for the detection of proliferating blood vessels
|van der Loos CM,Meijer-Jorna LB,Broekmans ME,Ploegmakers HP,Teeling P,de Boer OJ,van der Wal AC||The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (58:109)||2010|
Bevacizumab and breast cancer: current therapeutic progress and future perspectives.
MA5-12184 was used in immunohistochemistry to evaluate the efficacy of bevacizumab treatment for breast cancer
|Yang SX||Expert review of anticancer therapy (9:1715)||2009|
The differences between the endothelial area marked with CD31 and CD105 in colorectal carcinomas by computer-assisted morphometrical analysis.
MA5-12184 was used in immunohistochemistry to compare the CD31 and CD105 endothelial areas in colorectal carcinomas by computer-assisted morphometrical analysis
|Jung I,Gurzu S,Raica M,Cîmpean AM,Szentirmay Z||Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie (50:239)||2009|
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
MA5-12184 was used in immunohistochemistry to investigate the prognostic significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms in breast cancer treatment
|Schneider BP,Wang M,Radovich M,Sledge GW,Badve S,Thor A,Flockhart DA,Hancock B,Davidson N,Gralow J,Dickler M,Perez EA,Cobleigh M,Shenkier T,Edgerton S,Miller KD||Journal of clinical oncology : official journal of the American Society of Clinical Oncology (26:4672)||2008|
The expression of cytoskeleton regulatory protein Mena in colorectal lesions.
MA5-12184 was used in immunohistochemistry to investigate the expression of mammalian actin regulatory protein Ena in colorectal lesions
|Gurzu S,Jung I,Prantner I,Ember I,Pávai Z,Mezei T||Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie (49:345)||2008|
Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas.
MA5-12184 was used in immunohistochemistry to study the expression of HIF-1alpha, VEGF and GLUT-1 in endometrioid type endometrium adenocarcinomas
|Ozbudak IH,Karaveli S,Simsek T,Erdogan G,Pestereli E||Gynecologic oncology (108:603)||2008|
Vascular endothelial growth factor expression and vascularity in renal allograft biopsies.
MA5-12184 was used in immunohistochemistry to investigate the relationship between vascular endothelial growth factor expression and the pathology in renal allograft biopsies
|Sario¿lu S,Celik A,Er¿en A,Uçer I,Sa¿lam F,Camsari T,Gülay H||Transplantation proceedings (40:178)||2008|
Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
MA5-12184 was used in immunohistochemistry to investigate the prognostic biomarkers in stage IB-IIIA non-small cell lung cancer
|Timotheadou E,Skarlos DV,Samantas E,Papadopoulos S,Murray S,Skrickova J,Christodoulou C,Papakostantinou C,Pectasides D,Papakostas P,Kaplanova J,Vrettou E,Karina M,Kosmidis P,Fountzilas G||Anticancer research (27:4481)||2008|
Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival.
MA5-12184 was used in immunohistochemistry to evaluate the prognostic markers for early-stage gastric tumors
|Cabuk D,Basaran G,Celikel C,Dane F,Yumuk PF,Iyikesici MS,Ekenel M,Turhal NS||Oncology (72:111)||2007|
Effects of stobadine and vitamin E in diabetes-induced retinal abnormalities: involvement of oxidative stress.
MA5-12184 was used in immunohistochemistry to investigate the therapeautical benefits of stobadine and vitamin E in diabetes-induced retinal abnormalities
|Yülek F,Or M,Ozo¿ul C,Isik AC,Ari N,Stefek M,Bauer V,Karasu C||Archives of medical research (38:503)||2007|
Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma.
MA5-12184 was used in immunohistochemistry to investigate the role of the HIF-2alpha/EPAS1 in hepatocellular carcinoma
|Bangoura G,Liu ZS,Qian Q,Jiang CQ,Yang GF,Jing S||World journal of gastroenterology (13:3176)||2007|
Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
MA5-12184 was used in immunohistochemistry to identify prognostic markers for clear cell renal cell carcinoma
|Phuoc NB,Ehara H,Gotoh T,Nakano M,Yokoi S,Deguchi T,Hirose Y||Urology (69:843)||2007|
Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters.
MA5-12184 was used in immunohistochemistry to study the relationship between microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors
|Bolat F,Kayaselcuk F,Nursal TZ,Yagmurdur MC,Bal N,Demirhan B||Journal of experimental and clinical cancer research : CR (25:365)||2006|
Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate.
MA5-12184 was used in immunohistochemistry to study the effects of a 5-alpha reductase inhibitor on vascularity and VEGF expression in the rat prostate
|Canda AE,Mungan MU,Yilmaz O,Yorukoglu K,Tuzel E,Kirkali Z||International urology and nephrology (38:275)||2006|
Oxygen-induced retinopathy in mice with retinal photoreceptor cell degeneration.
MA5-12184 was used in western blot to study retinal neovascularization during oxygen-induced retinopathy in mice with photoreceptor cell degeneration
|Zhang Q,Zhang ZM||Life sciences (102:28)||2014|
The impact of KRAS mutations on VEGF-A production and tumour vascular network.
MA5-12184 was used in western blot to study the differential effects on the production of VEGF-A and tumor vasculature development of codon 12 and codon 13 KRAS mutations
|Figueras A,Arbos MA,Quiles MT,Viñals F,Germà JR,Capellà G||BMC cancer (13:null)||2013|
Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice.
MA5-12184 was used in western blot to investigate the effect of the overexpression of GLUT1 in podocytes on the mesangial matrix expansion in rodent diabetic nephropathy
|Zhang H,Schin M,Saha J,Burke K,Holzman LB,Filipiak W,Saunders T,Xiang M,Heilig CW,Brosius FC||American journal of physiology. Renal physiology (299:F91)||2010|
PGE1 analog alprostadil induces VEGF and eNOS expression in endothelial cells.
MA5-12184 was used in western blot to study the role of the PGE1 analog alprostadil in inducing VEGF and eNOS expression in endothelial cells
|Haider DG,Bucek RA,Giurgea AG,Maurer G,Glogar H,Minar E,Wolzt M,Mehrabi MR,Baghestanian M||American journal of physiology. Heart and circulatory physiology (289:H2066)||2005|
Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma.
MA5-12184 was used in immunohistochemistry - paraffin section to report the clinicopathological features of 9 breast malignant fibrous histiocytoma patients
|Qiu SQ,Wei XL,Huang WH,Wu MY,Qin YS,Li YK,Zhang GJ||Scientific reports (3:null)||2013|
Effects of methylene blue, pentoxyphylline and enoxaparin on postoperative adhesion formation and markers of angiogenesis in a rat uterine horn model.
MA5-12184 was used in immunohistochemistry - paraffin section to investigate the role of postoperative adhesions during angiogenesis
|Boztosun A,Piçnak A,Kosar MI,Gulturk S,Cetin A||Clinical and experimental obstetrics and gynecology (39:89)||2012|
Identification of prognostic biomarkers for glioblastomas using protein expression profiling.
MA5-12184 was used in immunohistochemistry - paraffin section to identify diagnostic and prognostic markers for glioblastoma
|Jung Y,Joo KM,Seong DH,Choi YL,Kong DS,Kim Y,Kim MH,Jin J,Suh YL,Seol HJ,Shin CS,Lee JI,Kim JH,Song SY,Nam DH||International journal of oncology (40:1122)||2012|
|Not Applicable||Not Cited||
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
MA5-12184 was used in immunohistochemistry - paraffin section to investigate the parameters for the identification of multiple myeloma patients suitable for bortezomib therapy
|Dawson MA,Opat SS,Taouk Y,Donovan M,Zammit M,Monaghan K,Horvath N,Roberts AW,Prince HM,Hertzberg M,McLean CA,Spencer A||Clinical cancer research : an official journal of the American Association for Cancer Research (15:714)||2009|
Vascular endothelial growth factor A; vascular endothelial growth factor A121; vascular endothelial growth factor A165; Vascular permeability factor; VEGF-A; VPF
MVCD1; VEGF; VEGFA; VPF